Abstract
The hepatitis B virus (HBV) infection is a public health problem worldwide, particularly in East Asia. The current therapy of HBV infection is mostly based on chemical agents and cytokines that have been shown to provide limited efficacy and are also toxic to the human body. Gene therapy is a new therapeutic strategy against HBV infection, involving the transmission of gene drugs into liver cells by specific delivery systems and methods. Although this new anti-HBV infection technique is under active investigation, various promising anti-HBV viral gene drugs have been developed for gene therapy, including antisense RNA and DNA, hammerhead ribozymes, dominant negative HBV core mutants, single chain antibody, co-nuclease fusion protein, and antigen. In order to optimize their antiviral effects and / or enhance anti-HBV immunity, various novel gene delivery systems have also been developed to (specifically) deliver such DNA constructs into liver cells; some of them are viral vectors, such as adenoviral vectors, retroviral vectors and poxviral vectors, and even hepatitis B viral for its hepatocellular specificity. Others are non-viral vectors, in which naked DNA and liposomes are frequently used for DNA vaccine or nucleotide analogs for inhibiting HBV DNA polymerase. This review addresses various aspects of gene therapy for HBV infection, including gene drugs, delivery methods, animal model, and liver transplantation with combination therapy. It also discusses the problems that remain to be solved.
Keywords: hepatitis B virus (HBV), DNA polymerase, hammerhead ribozymes
Current Gene Therapy
Title: Molecular Therapeutics of HBV
Volume: 3 Issue: 4
Author(s): Ruian Xu, Kexia Cai, Dexian Zheng, Hong Ma, Sue Xu and Sheung-tat Fan
Affiliation:
Keywords: hepatitis B virus (HBV), DNA polymerase, hammerhead ribozymes
Abstract: The hepatitis B virus (HBV) infection is a public health problem worldwide, particularly in East Asia. The current therapy of HBV infection is mostly based on chemical agents and cytokines that have been shown to provide limited efficacy and are also toxic to the human body. Gene therapy is a new therapeutic strategy against HBV infection, involving the transmission of gene drugs into liver cells by specific delivery systems and methods. Although this new anti-HBV infection technique is under active investigation, various promising anti-HBV viral gene drugs have been developed for gene therapy, including antisense RNA and DNA, hammerhead ribozymes, dominant negative HBV core mutants, single chain antibody, co-nuclease fusion protein, and antigen. In order to optimize their antiviral effects and / or enhance anti-HBV immunity, various novel gene delivery systems have also been developed to (specifically) deliver such DNA constructs into liver cells; some of them are viral vectors, such as adenoviral vectors, retroviral vectors and poxviral vectors, and even hepatitis B viral for its hepatocellular specificity. Others are non-viral vectors, in which naked DNA and liposomes are frequently used for DNA vaccine or nucleotide analogs for inhibiting HBV DNA polymerase. This review addresses various aspects of gene therapy for HBV infection, including gene drugs, delivery methods, animal model, and liver transplantation with combination therapy. It also discusses the problems that remain to be solved.
Export Options
About this article
Cite this article as:
Xu Ruian, Cai Kexia, Zheng Dexian, Ma Hong, Xu Sue and Fan Sheung-tat, Molecular Therapeutics of HBV, Current Gene Therapy 2003; 3 (4) . https://dx.doi.org/10.2174/1566523034578294
DOI https://dx.doi.org/10.2174/1566523034578294 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Melatonin Signaling in Health and Disease
Melatonin regulates a multitude of physiological functions, including circadian rhythms, acting as a scavenger of free radicals, an anti-inflammatory agent, a modulator of mitochondrial homeostasis, an antioxidant, and an enhancer of nitric oxide bioavailability. AANAT is the rate-limiting enzyme responsible for converting serotonin to NAS, which is further converted to ...read more
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers.
Programmed cell death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
The now and future of gene transfer technologies
Gene and cell therapies rely on a gene delivery system which is safe and effective. Both viral and non-viral vector systems are available with specific pros and cons. The choice of a vector system is largely dependent on the application which is a balance between target tissue/disease and safety, efficacy ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Identification of Molecular Targets Associated with Ethanol Toxicity and Implications in Drug Development
Current Pharmaceutical Design Importance of Aquaporins in the Physiopathology of Brain Edema
Current Pharmaceutical Design Pharmacological Screening of Lantana camara for its Antiallergic Activity in Rodents
Clinical Anti-Inflammatory & Anti-Allergy Drugs (Discontinued) CSF as a Surrogate for Assessing CNS Exposure: An Industrial Perspective
Current Drug Metabolism IBD Modern Concepts, Nano Drug Delivery and Patents: An Update
Recent Patents on Nanomedicine GABAA Receptors, Anesthetics and Anticonvulsants in Brain Development
CNS & Neurological Disorders - Drug Targets Bioactive Constituents from an Endophytic Fungus, Penicillium polonicum NFW9, Associated with Taxus fauna
Medicinal Chemistry Anxiety: A Systematic Review of Neurobiology, Traditional Pharmaceuticals and Novel Alternatives from Medicinal Plants
CNS & Neurological Disorders - Drug Targets Editorial [Hot Topic:Ion Channels as a Target for Drug Design (Executive Editor: Kwok-Keung Tai)]
Current Pharmaceutical Design Synthesis and Evaluation of Phenyliminoindolin-Containing Phenylacetamide Derivatives with the Antidepressant and Anticonvulsant Effects
Medicinal Chemistry HIV-1, HCV and Alcohol in the CNS: Potential Interactions and Effects on Neuroinflammation
Current HIV Research Anticonvulsant Sulfonamides/Sulfamates/Sulfamides with Carbonic Anhydrase Inhibitory Activity: Drug Design and Mechanism of Action
Current Pharmaceutical Design Genome-Wide Expression Analysis of Valproate Action: A Systems Level Synthesis
Current Psychopharmacology Menthone Aryl Acid Hydrazones: A New Class of Anticonvulsants
Medicinal Chemistry Emerging Pharmacological Properties of Cholinergic Synaptic Transmission: Comparison between Mammalian and Insect Synaptic and Extrasynaptic Nicotinic Receptors
Current Neuropharmacology The Role of Blood-Brain Barrier Studies in the Pharmaceutical Industry
Current Drug Metabolism Clinical Trials for Neuroprotection in ALS
CNS & Neurological Disorders - Drug Targets Mathematical Modelling and Feature Extraction for Probing Crucial Changes Associated with Alzheimers Disease
Current Medical Imaging Nutraceuticals, Nutritional Therapy, Phytonutrients, and Phytotherapy for Improvement of Human Health: A Perspective on Plant Biotechnology Application
Recent Patents on Biotechnology Synthesis and Evaluation of the Anticonvulsant Activities of New 5-substitued-[1,2,4]triazolo[4,3-a]quinoxalin-4(5H)-one Derivatives
Letters in Drug Design & Discovery